Research & Literature

Cutaneous Manifestations in Dermatomyositis: Key Clinical and Serological Features-a Comprehensive Review.

Muro Y, Sugiura K, Akiyama M

Clinical reviews in allergy & immunology 2016; (51(3)):293-302 doi:10.1007/s12016-015-8496-5.

[Dermatomyositis-update].

Volc-Platzer B

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 2015; (66(8)):604-10 doi:10.1007/s00105-015-3659-0.

Treatment of inflammatory myopathy: emerging therapies and therapeutic targets.

Moghadam-Kia S, Aggarwal R, Oddis CV

Expert review of clinical immunology 2015; (11(11)):1265-75 doi:10.1586/1744666X.2015.1082908.

A case of Amyopathic Dermatomyositis associated with Interstitial Pulmonary Disease.

Ugan Y, Sahin M, Dogru A, et al.

La Clinica terapeutica 2015; (166(6)):253-5 doi:10.7417/CT.2015.1897.

Biomarkers and Autoantibodies of Interstitial Lung Disease with Idiopathic Inflammatory Myopathies.

Yoshifuji H

Clinical medicine insights. Circulatory, respiratory and pulmonary medicine 2015; (9(Suppl 1)):141-6 doi:10.4137/CCRPM.S36748.

Statin-Associated Side Effects.

Thompson PD, Panza G, Zaleski A, Taylor B

Journal of the American College of Cardiology 2016; (67(20)):2395-2410 doi:10.1016/j.jacc.2016.02.071.

Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease.

Nakashima R, Hosono Y, Mimori T

Lupus 2016; (25(8)):925-33 doi:10.1177/0961203316651748.

Paraneoplastic syndrome and underlying breast cancer: a worsening rash despite initiation of chemotherapy.

Ahuja S, Makkar P, Gupta S, Vigoda I

The Journal of community and supportive oncology 2016; (14(5)):229-31 doi:10.12788/jcso.0186.

Autoantibodies in adult patients with idiopathic inflammatory myopathies in Buenos Aires.

Gómez GN, Gargiulo Mde L, Pérez N, et al.

Medicina 2016; (76(3)):129-34.

B-Cell Depletion Salvage Therapy in Rapidly Progressive Dermatomyositis Related Interstitial Lung Disease.

Eissa K, Palomino J

The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society 2016; (168(3)):99-100.

Clinical characteristics of patients with anti-TIF1-γ antibodies.

Masiak A, Kulczycka J, Czuszyńska Z, Zdrojewski Z

Reumatologia 2016; (54(1)):14-8 doi:10.5114/reum.2016.58756.

[New insights of myositis-specific and -associated autoantibodies in juvenile and adult type myositis].

Váncsa A, Dankó K

Orvosi hetilap 2016; (157(30)):1179-84 doi:10.1556/650.2016.30404.

Recent advances in dermatomyositis-specific autoantibodies.

Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N

Current opinion in rheumatology 2016; (28(6)):636-44 doi:10.1097/BOR.0000000000000329.

Risk of Malignancy in Dermatomyositis and Polymyositis.

Qiang JK, Kim WB, Baibergenova A, Alhusayen R

Journal of cutaneous medicine and surgery 2017; (21(2)):131-136 doi:10.1177/1203475416665601.

[Role of magnetic resonance imaging in the diagnosis of juvenile dermato-myositis and polymyositis in Chinese children].

Lai JM, Wu FQ, Zhou ZX, et al.

Zhonghua er ke za zhi = Chinese journal of pediatrics 2016; (54(10)):767-772 doi:10.3760/cma.j.issn.0578-1310.2016.10.011.

How Often are Pediatric Patients with Clinically Amyopathic Dermatomyositis Truly Amyopathic?

Oberle EJ, Bayer ML, Chiu YE, Co DO

Pediatric dermatology 2017; (34(1)):50-57 doi:10.1111/pde.13013.

Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.

Hozumi H, Fujisawa T, Nakashima R, et al.

Respiratory medicine 2016; (121()):91-99 doi:10.1016/j.rmed.2016.10.019.

Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients.

Foreman C, Russo P, Davies N, et al.

Internal medicine journal 2017; (47(1)):112-115 doi:10.1111/imj.13308.

Breast cancer and dermatomyositis: a case study and literature review.

Hendren E, Vinik O, Faragalla H, Haq R

Current oncology (Toronto, Ont.) 2017; (24(5)):e429-e433 doi:10.3747/co.24.3696.

Recent developments on treatment strategies and the prognosis of dermatomyositis: a review.

Isak V, Jorizzo JL

The Journal of dermatological treatment 2018; (29(5)):450-459 doi:10.1080/09546634.2017.1403549.

Evidence supports blind screening for internal malignancy in dermatomyositis: Data from 2 large US dermatology cohorts.

Leatham H, Schadt C, Chisolm S, et al.

Medicine 2018; (97(2)):e9639 doi:10.1097/MD.0000000000009639.

Anti-MDA5 antibody-positive hypomyopathic dermatomyositis complicated with pneumomediastinum.

Yashiro M, Asano T, Sato S, et al.

Fukushima journal of medical science 2018; (64(2)):89-94 doi:10.5387/fms.2018-01.

Scanxiety.

Portman D

Families, systems & health : the journal of collaborative family healthcare 2018; (36(3)):415 doi:10.1037/fsh0000353.

Characteristics and predictors of malignancy in dermatomyositis: Analysis of 239 patients from northern China.

Liu Y, Xu L, Wu H, et al.

Oncology letters 2018; (16(5)):5960-5968 doi:10.3892/ol.2018.9409.

Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.

Sakamoto N, Ishimoto H, Nakashima S, et al.

Internal medicine (Tokyo, Japan) 2019; (58(6)):837-841 doi:10.2169/internalmedicine.1516-18.

Use of Anti-transcriptional Intermediary Factor-1 Gamma Autoantibody in Identifying Adult Dermatomyositis Patients with Cancer: A Systematic Review and Meta-analysis.

Best M, Molinari N, Chasset F, et al.

Acta dermato-venereologica 2019; (99(3)):256-262 doi:10.2340/00015555-3091.

Positron emission tomography costs less to patients than conventional screening for malignancy in dermatomyositis.

Kundrick A, Kirby J, Ba D, et al.

Seminars in arthritis and rheumatism 2019; (49(1)):140-144 doi:10.1016/j.semarthrit.2018.10.021.

Dermatomyositis as a paraneoplastic phenomenon in oesophageal cancer.

Laidler NK

BMJ case reports 2018; (11(1)) doi:10.1136/bcr-2018-227387.

Heart⁻Lung⁻Muscle Anti-SAE Syndrome: An Atypical Severe Combination.

Zamora E, Seder-Colomina E, Holgado S, et al.

Journal of clinical medicine 2018; (8(1)) doi:10.3390/jcm8010020.

Autoantibodies in idiopathic inflammatory myopathies: Clinical associations and laboratory evaluation by mono- and multispecific immunoassays.

Damoiseaux J, Vulsteke JB, Tseng CW, et al.

Autoimmunity reviews 2019; (18(3)):293-305 doi:10.1016/j.autrev.2018.10.004.

Refractory Cutaneous Dermatomyositis With Severe Scalp Pruritus Responsive to Apremilast.

Charlton D, Moghadam-Kia S, Smith K, et al.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2021; (27(8S)):S561-S562 doi:10.1097/RHU.0000000000000999.

[Dermatomyositis-like syndrome revealing statin-induced necrotizing autoimmune myopathy with anti-HMGCR antibodies].

Merlant M, Fite C, Kottler D, et al.

Annales de dermatologie et de venereologie 2019; (146(8-9)):550-556 doi:10.1016/j.annder.2018.12.010.

Clinical significance of myositis-specific autoantibodies.

Nakashima R

Immunological medicine 2018; (41(3)):103-112 doi:10.1080/25785826.2018.1531188.

A novel case of TIF1 gamma autoantibody positive dermatomyositis associated with a non-functional pancreatic neuroendocrine tumor.

Varedi D, Frigerio A, Scaife C, Hull C

Dermatology online journal 2019; (25(3)).

The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients.

Giancane G, Lavarello C, Pistorio A, et al.

Pediatric rheumatology online journal 2019; (17(1)):24 doi:10.1186/s12969-019-0326-5.

Hepatitis B virus-related liver cirrhosis complicated with dermatomyositis: A case report.

Zhang J, Wen XY, Gao RP

World journal of clinical cases 2019; (7(10)):1206-1212 doi:10.12998/wjcc.v7.i10.1206.

The role of cancer-associated autoantibodies as biomarkers in paraneoplastic myositis syndrome.

Lu X, Peng Q, Wang G

Current opinion in rheumatology 2019; (31(6)):643-649 doi:10.1097/BOR.0000000000000641.

Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.

Motegi SI, Sekiguchi A, Toki S, et al.

European journal of dermatology : EJD 2019; (29(5)):511-517 doi:10.1684/ejd.2019.3634.

[Clinical analysis for 108 cases of dermatomyositis].

Chen P, Xie J, Xiao R, et al.

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 2019; (44(10)):1157-1162 doi:10.11817/j.issn.1672-7347.2019.180726.

Pneumocystis jirovecii Pneumonia and Other Infections in Idiopathic Inflammatory Myositis.

Mecoli CA, Danoff SK

Current rheumatology reports 2020; (22(2)):7 doi:10.1007/s11926-020-0883-0.

Rare occurrence of central diabetes insipidus with dermatomyositis in a young male.

Ekhzaimy A, Masood A, Alzahrani S, et al.

Endocrinology, diabetes & metabolism case reports 2020; (2020()).

Predictors of progression in systemic sclerosis patients with interstitial lung disease.

Distler O, Assassi S, Cottin V, et al.

The European respiratory journal 2020; (55(5)) doi:10.1183/13993003.02026-2019.

Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment.

Shirakashi M, Nakashima R, Tsuji H, et al.

Rheumatology (Oxford, England) 2020; (59(11)):3284-3292 doi:10.1093/rheumatology/keaa123.

The early local and systemic Type I interferon responses to ultraviolet B light exposure are cGAS dependent.

Skopelja-Gardner S, An J, Tai J, et al.

Scientific reports 2020; (10(1)):7908 doi:10.1038/s41598-020-64865-w.

Autoimmune Conditions: Polymyalgia Rheumatica and Dermatomyositis.

Ghetu MV

FP essentials 2020; (494()):25-29.

Assessment of diagnostic utility, clinical phenotypic associations, and prognostic significance of anti-NXP2 autoantibody in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis.

Li L, Liu C, Cheng L, et al.

Clinical rheumatology 2021; (40(3)):819-832 doi:10.1007/s10067-020-05291-1.

Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies.

Wong VT, So H, Lam TT, Yip RM

Acta neurologica Scandinavica 2021; (143(2)):131-139 doi:10.1111/ane.13331.

Paraneoplastic dermatomyositis associated with metastatic leiomyosarcoma of unknown primary.

Merry E, Smrke A, Halai K, et al.

Clinical sarcoma research 2020; (10()):15 doi:10.1186/s13569-020-00140-w.

Up-to-date treatment and management of myositis.

Pipitone N, Salvarani C

Current opinion in rheumatology 2020; (32(6)):523-527 doi:10.1097/BOR.0000000000000745.

Dermatomyositis: A Presenting Clinical Vignette in a Patient With Breast Cancer.

Allouch A, Zaatarikahale TB, Moussa MK, et al.

Cureus 2020; (12(9)):e10624 doi:10.7759/cureus.10624.

Erythematous auricular papules in the fatal cases of anti-MDA5 antibody-positive interstitial lung disease.

Intapiboon P, Siripaitoon B

Respiratory medicine case reports 2020; (31()):101299 doi:10.1016/j.rmcr.2020.101299.

Clinical characteristics of anti-MDA5 antibody-positive interstitial lung disease.

Kaenmuang P, Navasakulpong A

Respirology case reports 2021; (9(1)):e00701 doi:10.1002/rcr2.701.

Iacta Alea Est: The Inexorable Advance of Tofacitinib in the Treatment of Dermatomyositis-Associated Rapidly Progressive Interstitial Lung Disease. A Case Report.

Conca W, Weheba I, Abouzied ME, et al.

Frontiers in pharmacology 2020; (11()):585761 doi:10.3389/fphar.2020.585761.

A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies.

Oldroyd AGS, Allard AB, Callen JP, et al.

Rheumatology (Oxford, England) 2021; (60(6)):2615-2628 doi:10.1093/rheumatology/keab166.

Dermatomyositis with exfoliation of esophageal mucosa: A case report.

Zheng W, Zhang H, Zhang X, Liu Y

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 2021; (46(1)):104-107 doi:10.11817/j.issn.1672-7347.2021.190258.

Predictors, outcome and characteristics of oropharyngeal dysphagia in idiopathic inflammatory myopathy.

Labeit B, Perlova K, Pawlitzki M, et al.

Muscle & nerve 2021; (63(6)):874-880 doi:10.1002/mus.27225.

Treatment challenges in clinically amyopathic dermatomyositis: A case series and review of new therapeutic options for skin involvement.

Rodríguez-Tejero A, López-Espadafor B, Montero-Vílchez T, et al.

Dermatologic therapy 2021; (34(3)):e14942 doi:10.1111/dth.14942.

The pathophysiological effects of exercise in the management of idiopathic inflammatory myopathies: A scoping review.

Coskun Benlidayi I, Gupta L

International journal of rheumatic diseases 2021; (24(7)):896-903 doi:10.1111/1756-185X.14104.

Juvenile Dermatomyositis: Advances in Pathogenesis, Assessment, and Management.

Leung AKC, Lam JM, Alobaida S, et al.

Current pediatric reviews 2021; (17(4)):273-287 doi:10.2174/1573396317666210426105045.

Management of Myositis-Associated Interstitial Lung Disease.

Fujisawa T

Medicina (Kaunas, Lithuania) 2021; (57(4)) doi:10.3390/medicina57040347.

Myasthenia gravis with inflammatory myopathy without elevation of creatine kinase.

Kanbayashi T, Tanaka S, Hatanaka Y, et al.

Neuromuscular disorders : NMD 2021; (31(6)):570-573 doi:10.1016/j.nmd.2021.03.010.

A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer.

Piras M, Panebianco M, Garibaldi M, et al.

Current oncology (Toronto, Ont.) 2021; (28(3)):1957-1961 doi:10.3390/curroncol28030182.

Idiopathic inflammatory myopathies: a review.

Ashton C, Paramalingam S, Stevenson B, et al.

Internal medicine journal 2021; (51(6)):845-852 doi:10.1111/imj.15358.

Myositis-specific antibodies and clinical characteristics in patients with autoimmune inflammatory myopathies: reported by the Argentine Registry of Inflammatory Myopathies of the Argentine Society of Rheumatology.

Gómez GN, Pérez N, Braillard Poccard A, et al.

Clinical rheumatology 2021; (40(11)):4473-4483 doi:10.1007/s10067-021-05797-2.

Successful Treatment of Anti-MDA5 Antibody-Positive Dermatomyositis-Associated Rapidly Progressive-Interstitial Lung Disease by Plasma Exchange: Two Case Reports.

Takahashi R, Yoshida T, Morimoto K, et al.

Clinical medicine insights. Case reports 2021; (14()):11795476211036322 doi:10.1177/11795476211036322.

Rituximab as a glucocorticoid-sparing agent in idiopathic inflammatory myopathies: a retrospective single-center cohort study.

Egeli BH, Ergun S, Cetin A, et al.

Clinical rheumatology 2022; (41(1)):123-127 doi:10.1007/s10067-021-05871-9.

Characteristics and Predictors of Progression Interstitial Lung Disease in Rheumatoid Arthritis Compared with Other Autoimmune Disease: A Retrospective Cohort Study.

Mena-Vázquez N, Rojas-Gimenez M, Romero-Barco CM, et al.

Diagnostics (Basel, Switzerland) 2021; (11(10)) doi:10.3390/diagnostics11101794.

Anti-TIF-1α/γ Antibody-Positive Dermatomyositis Associated With Metastatic Prostatic Adenocarcinoma.

Psomadakis CE, Maron SZ, Ng MJ, et al.

Journal of clinical neuromuscular disease 2021; (23(2)):100-104 doi:10.1097/CND.0000000000000378.

A Study on Dermatomyositis and the Relation to Malignancy.

Tudorancea AD, Ciurea PL, Vreju AF, et al.

Current health sciences journal 2021; (47(3)):377-382 doi:10.12865/CHSJ.47.03.07.

A Man With Recurrent Pneumonitis: A Rare Case of Interstitial Lung Disease Associated With Anti-Mi-2 Beta-Specific Dermatomyositis.

Ahmad A, Attoti Y, Bernstein KA

Cureus 2021; (13(12)):e20334 doi:10.7759/cureus.20334.

Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: A systematic review.

McPherson M, Economidou S, Liampas A, et al.

Seminars in arthritis and rheumatism 2022; (53()):151959 doi:10.1016/j.semarthrit.2022.151959.

Autoantibody Markers of Increased Risk of Malignancy in Patients with Dermatomyositis.

Marzęcka M, Niemczyk A, Rudnicka L

Clinical reviews in allergy & immunology 2022; (63(2)):289-296 doi:10.1007/s12016-022-08922-4.

Case Report: Concurrence of Dermatomyositis and Autoimmune Blistering Diseases: Two Case Reports and a Literature Review.

Wu H, Diao L, Xue K, et al.

Frontiers in immunology 2022; (13()):855408 doi:10.3389/fimmu.2022.855408.

Severe Paraneoplastic Dermatomyositis in a Patient With High-Grade Serous Ovarian Cancer.

Lajoie C, Brault C, Fortin S, et al.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 2022; (44(6)):700-702 doi:10.1016/j.jogc.2022.01.015.

The Utility of Myositis Specific Antibodies in Clinical Practice.

Biddle K, Taylor MD, Linstead SE, Kiely PDW

The journal of applied laboratory medicine 2022; (7(5)):1189-1201 doi:10.1093/jalm/jfac038.

Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review.

Paik JJ, Lubin G, Gromatzky A, et al.

Clinical and experimental rheumatology 2023; (41(2)):348-358 doi:10.55563/clinexprheumatol/hxin6o.

Subsets of Idiopathic Inflammatory Myositis Enriched for Contemporaneous Cancer Relative to the General Population.

Mecoli CA, Igusa T, Chen M, et al.

Arthritis & rheumatology (Hoboken, N.J.) 2023; (75(4)):620-629 doi:10.1002/art.42311.

Anti-MDA5 Amyopathic Dermatomyositis-A Diagnostic and Therapeutic Challenge.

Bobirca A, Alexandru C, Musetescu AE, et al.

Life (Basel, Switzerland) 2022; (12(8)) doi:10.3390/life12081108.

Cancer and myositis: Who, when, and how to screen.

Kardes S, Gupta L, Aggarwal R

Best practice & research. Clinical rheumatology 2022; (36(2)):101771 doi:10.1016/j.berh.2022.101771.

Effects of a 360° virtual counselling environment on patient anxiety and CCTA process time: A randomised controlled trial.

Paalimäki-Paakki K, Virtanen M, Henner A, et al.

Radiography (London, England : 1995) 2023; (29 Suppl 1()):S13-S23 doi:10.1016/j.radi.2022.09.013.

Clinical characteristics of and risk factors for Pneumocystis jirovecii pneumonia in anti-melanoma differentiation-associated gene 5 (Anti-MDA5) antibody-positive dermatomyositis patients: a single-center retrospective study.

Li J, Wang S, Zheng J, et al.

Clinical rheumatology 2023; (42(2)):453-462 doi:10.1007/s10067-022-06403-9.

Clinical and Radiological Features of Interstitial Lung Diseases Associated with Polymyositis and Dermatomyositis.

Palmucci S, Di Mari A, Cancemi G, et al.

Medicina (Kaunas, Lithuania) 2022; (58(12)) doi:10.3390/medicina58121757.

Compounded sulfamethoxazole improved the prognosis of dermatomyositis patients positive with anti-melanoma differentiation-associated gene 5.

Liu L, Zhang Y, Liu S, et al.

Rheumatology (Oxford, England) 2023; (62(9)):3095-3100 doi:10.1093/rheumatology/kead034.

Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.

Derry-Vick HM, Heathcote LC, Glesby N, et al.

Cancers 2023; (15(5)) doi:10.3390/cancers15051381.

Dermatomyositis autoantigen CHD4 forms immune stimulatory complexes with endogenous DNA.

Guel T, Scholtissek B, Siegl J, et al.

Experimental dermatology 2023; (32(7)):965-974 doi:10.1111/exd.14799.

Anti-SAE autoantibody in dermatomyositis: original comparative study and review of the literature.

Demortier J, Vautier M, Chosidow O, et al.

Rheumatology (Oxford, England) 2023; (62(12)):3932-3939 doi:10.1093/rheumatology/kead154.

[Therapeutic Strategies for Idiopathic Inflammatory Myopathies].

Tomimitsu H

Brain and nerve = Shinkei kenkyu no shinpo 2023; (75(5)):511-516 doi:10.11477/mf.1416202369.

Intravenous Immunoglobulin in Idiopathic Inflammatory Myopathies: a Practical Guide for Clinical Use.

Gandiga PC, Ghetie D, Anderson E, Aggrawal R

Current rheumatology reports 2023; (25(8)):152-168 doi:10.1007/s11926-023-01105-w.

Malignancy in dermatomyositis: a mono-centric retrospective study of 134 patients in China and a potential predictive model.

Tang ZL, Chi CC, Tang ZW, et al.

Frontiers in medicine 2023; (10()):1200804 doi:10.3389/fmed.2023.1200804.

[Clinically amyopathic dermatomyositis : a rare entity associated with acute and severe interstitial lung disease].

Debrus C, Calmes D, Von Frenckell C, et al.

Revue medicale de Liege 2023; (78(7-8)):441-447.

Narrowband Intense Pulsed Light Treatment for Refractory Facial Rash Associated with Dermatomyositis.

Zheng Y, Cai S

Clinical, cosmetic and investigational dermatology 2023; (16()):2481-2484 doi:10.2147/CCID.S426762.

Scan-Associated Distress in People Affected by Cancer: A Qualitative Systematic Review.

Hussain M, Chau S, Turner M, Paterson C

Seminars in oncology nursing 2023; (39(5)):151502 doi:10.1016/j.soncn.2023.151502.

Cancer Screening for Dermatomyositis: A Survey of Indirect Costs, Burden, and Patient Willingness to Pay.

Jicha KI, Bazewicz CG, Helm MF, et al.

Cutis 2023; (112(2)):89-95 doi:10.12788/cutis.0833.

International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative.

Oldroyd AGS, Callen JP, Chinoy H, et al.

Nature reviews. Rheumatology 2023; (19(12)):805-817 doi:10.1038/s41584-023-01045-w.

Imbalance of peripheral blood Th17/Treg increases neutrophil-to-lymphocyte ratio in patients with dermatomyositis.

Zhang Z, Pang J, Li Y, et al.

American journal of translational research 2023; (15(10)):6106-6114.

Aggressive multi-combination therapy for anti-MDA5 antibody-positive dermatomyositis-rapidly progressive interstitial lung disease.

Hata K, Kotani T, Matsuda S, et al.

International journal of rheumatic diseases 2024; (27(1)):e14999 doi:10.1111/1756-185X.14999.

[Current update on dermatomyositis].

Steininger J, Günther C

Dermatologie (Heidelberg, Germany) 2024; (75(2)):153-162 doi:10.1007/s00105-023-05273-9.

Research progress on the dermatomyositis specific autoantibodies and malignancy associated dermatomyositis.

Xu Y, Yang Y, Fan S

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 2023; (48(12)):1890-1898 doi:10.11817/j.issn.1672-7347.2023.220594.

Unveiling Dermatomyositis: A Tragic Tale of Mortality in a 23-Year-Old.

Deolikar V, Raut SS, Toshniwal S, et al.

Cureus 2024; (16(3)):e56058 doi:10.7759/cureus.56058.

Past, Present, and Future in Dermatomyositis Therapeutics.

Chung MP, Paik JJ

Current treatment options in rheumatology 2022; (8(4)):71-90 doi:10.1007/s40674-022-00193-6.

Two challenging cases of anti-MDA-5 dermatomyositis with rapidly progressive interstitial lung disease.

Biddle K, Agaoglu E, Brent G, et al.

Oxford medical case reports 2024; (2024(6)):omae061 doi:10.1093/omcr/omae061.

Prevalence and Clinical Implications of Autoantibodies in Juvenile Dermatomyositis: A Single-Center Experience From India.

Joseph AJ, Dhakal B, Erla SR, et al.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2024; (30(7)):271-275 doi:10.1097/RHU.0000000000002127.

Dermatomyositis in a young patient: A rare paraneoplastic syndrome of renal cell carcinoma.

André M, Macedo A, Metrogos V, et al.

IJU case reports 2024; (7(5)):359-363 doi:10.1002/iju5.12754.

Validation of the International Myositis Assessment and Clinical Studies Group guideline on cancer risk stratification.

Tang IYK, Chan SCW, Li PH, et al.

Rheumatology (Oxford, England) 2025; (64(4)):2106-2114 doi:10.1093/rheumatology/keae504.

Patients with anti-small ubiquitin-like modifier activating enzyme-positive dermatomyositis resembling antisynthetase syndrome with poor prognosis: a bicentric international retrospective study and literature review.

De Carvalho CGV, Bayeh B, De Souza FHC, et al.

Reumatismo 2024; (77(1)) doi:10.4081/reumatismo.2024.1686.

Atypical presentation of anti-small ubiquitin-like modifier 1 and melanoma differentiation-associated gene 5 antibody positive dermatomyositis presenting with significant inflammatory myopathy on biopsy and normal creatine kinase levels: A case report.

Sama S, Rasheed N, Shen K, et al.

SAGE open medical case reports 2024; (12()):2050313X241298862 doi:10.1177/2050313X241298862.

Characteristics of Patients With Adult-Onset Dermatomyositis at 2 Tertiary Care Centres in Ontario, Canada.

Metko D, Bednar DE, Alkhayal F, et al.

Journal of cutaneous medicine and surgery 2025; (29(2)):124-130 doi:10.1177/12034754241301409.

Amyopathic Dermatomyositis with a Rapidly Progressing Interstitial Pneumonia.

Logvinova D, Žentiņa D, Ivanova K, et al.

European journal of case reports in internal medicine 2024; (11(12)):005036 doi:10.12890/2024_005036.

Clinical Features of Dermatomyositis Associated with Myositis-Specific Antibodies in Moroccan Patients.

Chihi M, Barakat L, Benhayoun FZ, et al.

Clinics and practice 2025; (15(2)) doi:10.3390/clinpract15020031.

A Clinical Picture of Amyopathic Dermatomyositis.

Dempsey B, Epstein D, Joseph C, et al.

Cureus 2025; (17(3)):e81246 doi:10.7759/cureus.81246.

Microvascular abnormalities between anti-TIF1-γ-associated dermatomyositis with and without malignancy.

Mumtaz S, Phillipps J, Sullivan MM, et al.

BMC rheumatology 2025; (9(1)):50 doi:10.1186/s41927-025-00504-z.

A case of anti-SAE antibody-positive dermatomyositis presenting with preceding panniculitis as the initial symptom.

Horimoto E, Ishizaki J, Muto J, et al.

Modern rheumatology case reports 2025; (9(2)) doi:10.1093/mrcr/rxaf029.

Analysis of clinical features and risk factors for patients with idiopathic inflammatory myopathy complicated by Pneumocystis jirovecii pneumonia.

Li J, Huang W, Ren F, et al.

Clinical and experimental rheumatology 2026; (44(2)):210-217 doi:10.55563/clinexprheumatol/fpbkc8.

Rituximab treatment of refractory skin involvement in anti-TIF1 gamma dermatomyositis.

Said F, Jridi M, Naceur I, et al.

Dermatology online journal 2025; (31(1)) doi:10.5070/D331164969.

Risk, risk factors, and screening of malignancies in dermatomyositis: current status and future perspectives.

Liu S, Zhang Z, Yan S, et al.

Frontiers in oncology 2025; (15()):1503140 doi:10.3389/fonc.2025.1503140.

Rehospitalization to evaluate outcomes during clinical courses in patients with elderly-onset idiopathic inflammatory myositis: a retrospective single-center study.

Kurashina JI, Shimojima Y, Kishida D, et al.

Clinical rheumatology 2025; (44(8)):3245-3251 doi:10.1007/s10067-025-07540-7.

Ruxolitinib in adult dermatomyositis with anti-TIF1γ antibody: a case report and literature review.

Jing X, Min W, Xia L, Shanshan L

Frontiers in immunology 2025; (16()):1591631 doi:10.3389/fimmu.2025.1591631.

Dermatomyositis: focus on cutaneous features, etiopathogenetic mechanisms and their implications for treatment.

Ali H, On A, Xing E, et al.

Seminars in immunopathology 2025; (47(1)):32 doi:10.1007/s00281-025-01054-9.

Paraneoplastic Dermatomyositis presenting as Supraglottitis and acute heart failure; a case report.

McCormick JP, Kenny A, Coyle M, et al.

Oxford medical case reports 2025; (2025(9)):omaf167 doi:10.1093/omcr/omaf167.

Tongue myositis in dermatomyositis with anti-PM-Scl 75 antibody: two case reports.

Sun C, Tian X, Li S, et al.

BMC musculoskeletal disorders 2025; (26(1)):868 doi:10.1186/s12891-025-09114-9.

Diagnostic challenges of dermatomyositis in a resource-limited setting: a case report.

Alemu GS, Ambaye MT

Journal of medical case reports 2025; (19(1)):478 doi:10.1186/s13256-025-05446-1.

Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

Shah MS, Memon JA, Malik U, et al.

Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

Management of Lung Manifestations in Idiopathic Inflammatory Myopathies.

Krishnan A, Jain S, Lammi MR

Rheumatic diseases clinics of North America 2025; (51(4)):623-641 doi:10.1016/j.rdc.2025.07.007.

Anifrolumab Therapy in Dermatomyositis: New Insights From Refractory Patients.

Carli L, Cavagna L, Cardelli C, et al.

The Journal of rheumatology 2026; (53(2)):180-185 doi:10.3899/jrheum.2025-0773.

VR-Based Anxiety Reduction Framework for Pediatric MRI Using Gamified Biofeedback.

Roberts DM, Chen J, Martinez LK, et al.

Research square 2025; doi:10.21203/rs.3.rs-7737172/v1.

Prognostic Implications of Myositis-Specific Autoantibodies on Mortality, Relapse, and Remission in Dermatomyositis Patients.

Hou Y, Ma X, Mu H, et al.

European journal of neurology 2025; (32(12)):e70446 doi:10.1111/ene.70446.

Intravenous immunoglobulin is an effective steroid-sparing drug in inflammatory myositis.

Nannarup A, Bartels LE, Næser EU

Danish medical journal 2025; (72(12)) doi:10.61409/A02250076.

Dermatomyositis in women: a 15-year retrospective analysis of clinical patterns, malignancy risk, and long-term outcomes at a tertiary center.

Malinić M, Reljić V, Vuković J, et al.

Acta dermatovenerologica Alpina, Pannonica, et Adriatica 2025; (34(4)):165-169.

A Diagnostic Delay: Respiratory Muscle Weakness in Dermatomyositis Masquerading as Pneumonia.

Jain M, Doddapaneni VK, Rahman B, Aslam N

Cureus 2025; (17(12)):e100112 doi:10.7759/cureus.100112.

Erythematous rash and proximal muscle weakness in a 59-year-old woman: Delayed diagnosis of dermatomyositis in a patient with skin of color.

Henry T, Hamaker M, Dhakal R, et al.

Journal of the National Medical Association 2026; doi:10.1016/j.jnma.2026.01.012.

Prophylactic Effect of Trimethoprim-sulfamethoxazole on Severe Infections in Idiopathic Inflammatory Myopathy.

Kogami M, Abe Y, Ando T, et al.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2026; doi:10.1097/RHU.0000000000002325.